Theriva Biologics continues to develop its lead oncolytic virus candidate VCN-01 for metastatic pancreatic cancer, supported by FDA Fast Track and Rare Disease designations. Despite operational milestones including Phase 2b enrollment completion and licensing deals such as SYN-020 with Rasayana Pharmaceuticals, the company faces ongoing financial strain with no revenue, an accumulated deficit of approximately $358.7 million, negative operating cash flow of $16.7 million in 2025, and $13.1 million in cash at year-end. Contingent milestone payments and limited runway into early 2027 underscore the need for additional capital to sustain operations. Investors should monitor clinical readouts, milestone developments, and financing strategies closely [F1][N1][N2][N3][S1][S3].